The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...